Belantamab mafodotin-blmf failed to extend PFS compared with pomalidomide and dexamethasone for adults with relapsed or refractory multiple myeloma, according to topline data from a confirmatory trial released by the agent’s manufacturer.
Belantamab mafodotin-blmf (Blenrep, GSK) is an antibody-drug conjugate comprising a humanized B-cell maturation antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent auristatin F via a non-cleavable linker.
The FDA granted accelerated approval to the agent in 2020 for adults with multiple myeloma who received at least four prior therapies,
